Dendritic cells as therapeutic vaccines against cancer
暂无分享,去创建一个
[1] C. Figdor,et al. Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.
[2] S. Miltenyi,et al. BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.
[3] S. Dzik. The nature of the principal type 1 interferon-producing cells in human blood , 2000 .
[4] Susan M. Kaech,et al. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. , 2002 .
[5] Michel C. Nussenzweig,et al. Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.
[6] Christoph Schaniel,et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation , 1998, European journal of immunology.
[7] Laurence Zitvogel,et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.
[8] Bali Pulendran,et al. Lipopolysaccharides from Distinct Pathogens Induce Different Classes of Immune Responses In Vivo1 , 2001, The Journal of Immunology.
[9] E. Margoliash,et al. T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes , 1979, The Journal of experimental medicine.
[10] B. Fox,et al. Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution , 2003, European journal of immunology.
[11] M. Jefford,et al. Rational approaches to human cancer immunotherapy , 2003, Journal of leukocyte biology.
[12] J. Banchereau,et al. Interleukin 15 Skews Monocyte Differentiation into Dendritic Cells with Features of Langerhans Cells , 2001, The Journal of experimental medicine.
[13] Wolfgang Weninger,et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells , 2003, Nature.
[14] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[15] K. Pang,et al. Type I IFNs enhance the terminal differentiation of dendritic cells. , 1998, Journal of immunology.
[16] Mitchell Kronenberg,et al. Toward an understanding of NKT cell biology: progress and paradoxes. , 2005, Annual review of immunology.
[17] Freddie H. Fu,et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. , 1996, Transplantation.
[18] R. Steinman,et al. Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma , 2003, Journal of immunotherapy.
[19] R. Förster,et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. , 2002, Blood.
[20] P. Gibbs,et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. , 2003, Cancer immunity.
[21] A. Enk,et al. Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.
[22] T. Schumacher,et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[23] J. Banchereau,et al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells , 1992, Nature.
[24] R. Zinkernagel. On natural and artificial vaccinations. , 2003, Annual review of immunology.
[25] N. Kadowaki,et al. The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.
[26] G. Nossal. Host immunobiology and vaccine development , 1997, The Lancet.
[27] C Caux,et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. , 1997, Blood.
[28] J. Sprent,et al. Stimulation of naive and memory T cells by cytokines , 1999, Immunological reviews.
[29] J. Davey,et al. Cytotoxic T cells recognize fragments of the influenza nucleoprotein , 1985, Cell.
[30] E. J. Foley. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953, Cancer research.
[31] T. Blankenstein,et al. B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.
[32] P. Kourilsky,et al. Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1 , 2004, The Journal of Immunology.
[33] Mark M. Davis,et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] P. Ricciardi-Castagnoli,et al. Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.
[35] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[36] J. Mayordomo,et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.
[37] S. Holmes,et al. Diversity and Recognition Efficiency of T Cell Responses to Cancer , 2004, PLoS medicine.
[38] D. Jarrossay,et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon , 1999, Nature Medicine.
[39] E. Wherry,et al. Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.
[40] J. Davoust,et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. , 2000, Immunity.
[41] R. Steinman,et al. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. , 1999, Immunity.
[42] J. Banchereau,et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha , 1996, The Journal of experimental medicine.
[43] V. Sondak,et al. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. , 2003, Seminars in cancer biology.
[44] Lukas Hunziker,et al. Dendritic cell–induced autoimmune heart failure requires cooperation between adaptive and innate immunity , 2003, Nature Medicine.
[45] Virginia Pascual,et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. , 2003, Immunity.
[46] N. Kadowaki,et al. Reciprocal control of T helper cell and dendritic cell differentiation. , 1999, Science.
[47] E. Shevach,et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.
[48] Hao Shen,et al. CD8+ T-cell memory: only the good ones last. , 2004, Current opinion in immunology.
[49] D. Pardoll,et al. Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.
[50] Wei Lu,et al. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection , 2004, Nature Medicine.
[51] R. Steinman,et al. The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.
[52] Edgar G. Engleman,et al. Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1 , 2001, The Journal of Immunology.
[53] E. Gilboa,et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.
[54] M. Moser,et al. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo , 1992, The Journal of experimental medicine.
[55] Yong‐jun Liu,et al. Mouse and human dendritic cell subtypes , 2002, Nature Reviews Immunology.
[56] S. Swain,et al. Reciprocal regulation of polarized cytokine production by effector B and T cells , 2000, Nature Immunology.
[57] R. Maldonado-López,et al. CD8α+ and CD8α− Subclasses of Dendritic Cells Direct the Development of Distinct T Helper Cells In Vivo , 1999, The Journal of experimental medicine.
[58] R. Coleman,et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.
[59] Nina Bhardwaj,et al. Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells , 2001, The Journal of experimental medicine.
[60] C. Reis e Sousa,et al. Dendritic cells as sensors of infection. , 2001, Immunity.
[61] T. Luft,et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. , 2002, Blood.
[62] D. Morton,et al. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. , 2003, Seminars in cancer biology.
[63] E. Gilboa,et al. Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts , 1997, International journal of cancer.
[64] Virginia Pascual,et al. Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.
[65] S. Rosenberg,et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.
[66] M. Peshwa,et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] M. Mescher,et al. Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma , 2004, Clinical Cancer Research.
[68] M. Albert,et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.
[69] O. Finn,et al. Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.
[70] N. Kadowaki,et al. Natural Interferon α/β–Producing Cells Link Innate and Adaptive Immunity , 2000, The Journal of experimental medicine.
[71] R. Steinman,et al. Immunotherapy: Bewitched, Bothered, and Bewildered No More , 2004, Science.
[72] A. Palucka,et al. TNF Skews Monocyte Differentiation from Macrophages to Dendritic Cells 1 , 2003, The Journal of Immunology.
[73] Antonio Lanzavecchia,et al. Regulation of T Cell Immunity by Dendritic Cells , 2001, Cell.
[74] Antonio Lanzavecchia,et al. Regulation of Dendritic Cell Migration to the Draining Lymph Node , 2003, The Journal of experimental medicine.
[75] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[76] R. Steinman,et al. Dendritic cells pulsed with protein antigens in vitro can prime antigen- specific, MHC-restricted T cells in situ [published erratum appears in J Exp Med 1990 Oct 1;172(4):1275] , 1990, The Journal of experimental medicine.
[77] J. Banchereau,et al. The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface , 1999, European journal of immunology.
[78] A. Zlotnik,et al. The biology of chemokines and their receptors. , 2000, Annual review of immunology.
[79] L. Kemény,et al. Skin cancers after organ transplantation. , 2003, The New England journal of medicine.
[80] R. Steinman,et al. Direct Expansion of Functional CD25+ CD4+ Regulatory T Cells by Antigen-processing Dendritic Cells , 2003, The Journal of experimental medicine.
[81] G. Coukos,et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.
[82] S. Imamura,et al. CD 34 + Hematopoietic Progenitors from Human Cord Blood Differentiate Along Two Independent Dendritic Cell Pathways in Response to GM-CSF + TNFoL , 2003 .
[83] D. Berd,et al. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. , 1988, Cancer research.
[84] T. Tüting,et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.
[85] V. Engelhard,et al. Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control , 2003, Journal of Experimental Medicine.
[86] A. Enk,et al. Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.
[87] B. Pulendran,et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[88] A. Enk,et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.
[89] P. Marrack,et al. Type I Interferons Keep Activated T Cells Alive , 1999, The Journal of experimental medicine.
[90] M. Bevan,et al. Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.
[91] Hervé Groux,et al. A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.
[92] J. Mulé,et al. Current developments of immunotherapy in the clinic. , 2004, Current opinion in immunology.
[93] W. Storkus,et al. B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .
[94] T. Brocker,et al. The role of dendritic cells in T cell selection and survival , 1999, Journal of leukocyte biology.
[95] D. Schadendorf,et al. Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma , 2000, Journal of immunotherapy.
[96] A. Aguzzi,et al. Dangerous Liaisons between a Microbe and the Prion Protein , 2003, The Journal of experimental medicine.
[97] D. Gabrilovich. Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.
[98] J. Mulé,et al. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[99] S. Rosenberg. Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.
[100] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[101] Edgar G. Engleman,et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.
[102] R. Medzhitov,et al. Toll-dependent control mechanisms of CD4 T cell activation. , 2004, Immunity.
[103] A Sette,et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.
[104] A. N. Park,et al. Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells , 1998, Journal of leukocyte biology.
[105] J. Banchereau,et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.
[106] Urs Christen,et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.
[107] C Caux,et al. Immunobiology of dendritic cells. , 2000, Annual review of immunology.
[108] J. Fay,et al. Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells , 2004, The Journal of experimental medicine.
[109] Loise M. Francisco,et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.
[110] J. Altman,et al. Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.
[111] P. Ricciardi-Castagnoli,et al. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.
[112] A. Palucka,et al. Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells , 2000, The Journal of experimental medicine.
[113] E. Gilboa. The makings of a tumor rejection antigen. , 1999, Immunity.
[114] A. Ribas,et al. Cancer immunotherapy using gene-modified dendritic cells. , 2002, Current gene therapy.
[115] S. Menzies,et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma , 2004, Cancer Immunology, Immunotherapy.
[116] D. Morton,et al. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. , 1990, Cancer research.
[117] G. Schuler,et al. Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.
[118] Kathleen M. Smith,et al. Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP , 2002, Nature Immunology.
[119] J. Peters,et al. Signals required for differentiating dendritic cells from human monocytes in vitro. , 1993, Advances in experimental medicine and biology.
[120] N. Kadowaki,et al. Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.
[121] T. Di Pucchio,et al. Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice , 2000, The Journal of experimental medicine.
[122] A. Enk,et al. Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells , 2000, The Journal of experimental medicine.
[123] H. Weiner,et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. , 1994, Science.
[124] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[125] R. North,et al. The murine antitumor immune response and its therapeutic manipulation. , 1984, Advances in immunology.
[126] A. Palucka,et al. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes , 2004, Breast Cancer Research.
[127] Foley Ej. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953 .
[128] R. Steinman,et al. Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.
[129] E. Gilboa,et al. Immunotherapy of cancer with dendritic-cell-based vaccines , 1998, Cancer Immunology, Immunotherapy.
[130] J. Kirkwood,et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.
[131] J. Cormier,et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.
[132] Hao Shen,et al. Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.
[133] M. Gilliet,et al. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. , 2003, Blood.
[134] E. Leventhal,et al. Aging, immunity, and cancer. , 2000, Cancer control : journal of the Moffitt Cancer Center.
[135] A. Naji,et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide , 2001, Nature Immunology.
[136] Antonio Lanzavecchia,et al. BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction , 2001, The Journal of experimental medicine.
[137] F. Marincola,et al. T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance , 2001, Expert opinion on biological therapy.
[138] Jay A. Berzofsky,et al. NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.
[139] L. Lanier,et al. Distinct Cytokine Profiles of Neonatal Natural Killer T Cells after Expansion with Subsets of Dendritic Cells , 2001, The Journal of experimental medicine.
[140] Concepción Marañón,et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope , 2003, Nature Immunology.
[141] M. Roncarolo,et al. Type 1 T regulatory cells , 2001, Immunological reviews.
[142] D. Neuberg,et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[143] E. Jaffee,et al. Cancer Vaccines , 1997, Current protocols in human genetics.
[144] R. Schreiber,et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.
[145] Ira Mellman,et al. Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.
[146] L. Lefrançois,et al. Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.
[147] Adelheid Cerwenka,et al. Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.
[148] R. Steinman,et al. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.
[149] R. Steinman,et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.